St. Vincent's Hospital Melbourne
St. Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2026-10-07 | NCT06528301 | |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-02 | NCT06500273 | |
| RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, epilepsy, focal epilepsy, nervous system disorder, visual epilepsy | Recruiting | Phase 2 | 2026-10-01 | NCT06798896 | |
| Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma | Relapsed and/or Refractory B-cell Lymphoma | Recruiting | Phase 1 / Phase 2 | 2026-09-25 | NCT04989803 | |
| Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Enrolling by invitation | Not applicable | 2026-09-24 | NCT07197788 | |
| A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 3 | 2026-09-18 | NCT07422480 | |
| A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH | metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 1 | 2026-08-03 | NCT05945537 | |
| A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, GATA2 deficiency with susceptibility to MDS/AML, Hemic and Lymphatic Diseases, Myelodysplastic Syndrome Acute Myeloid Leukemia, Neoplasms by Histologic Type, acute myeloid leukemia, anemia, bone marrow disorder, hematologic disorder, hereditary disease, leukemia, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2026-06-01 | NCT06372717 | |
| Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-04-01 | NCT05862012 | |
| SODium BICarbonate for Metabolic Acidosis in the ICU | Acid-Base Imbalance, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, acidosis disorder, metabolic acidosis, metabolic disease | Active, not recruiting | Phase 3 | 2026-03-27 | NCT05697770 | |
| Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, ischemic stroke, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Not applicable | 2026-03-24 | NCT05478304 | |
| Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-04 | NCT04416984 |